Haematology Educational Series - Management of Chronic Lymphocytic Leukaemia

This review summarises recent developments in the management of relapsed or refractory chronic lymphocytic leukaemia with emphasis on the use of the oral targeted agents, ibrutinib and idelalisib, from a clinical practice standpoint. This review is intended as an educational resource for clinical haematologists and haematology nurses.

Independent expert commentary provided by Associate Professor Bryone Kuss who is Head of Clinical
and Laboratory Haematology & Genetic Pathology, Flinders Medical Centre, SA.

Please login below to download this issue (PDF)